
Arrowhead misses the target in alpha-1 antitrypsin deficiency
The Takeda-partnered project fazirsiran shows an impressive reduction in mutant protein, but questions about fibrosis remain.

Clinical and corporate developments over the Christmas period
A decent showing for Pfizer/Roche in haemophilia sets up a rivalry with Uniqure/CSL, and a smattering of deals get done before the year end – and before JP Morgan.

Ash 2022 – toxicity still looms large for Regeneron’s bispecific
Another five treatment-related deaths, despite a dose regimen change, raise questions about whether odronextamab will be able to compete.

Gossamer unravels
The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.

Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?

CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.